These innovative agents represent a significant progression in the treatment of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in controlling blood glucose https://phoebeypth426778.newsbloger.com/39788077/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide